Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction.
bronchiolitis obliterans (BOS)
clinical research/practice
infection and infectious agents-viral
infectious disease
lung (allograft) function/dysfunction
lung transplantation/pulmonology
molecular biology: DNA
translational research/science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
15
06
2022
received:
25
02
2022
accepted:
15
06
2022
pubmed:
23
6
2022
medline:
10
11
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Respiratory viral infection (RVI) in lung transplant recipients (LTRs) is a risk for chronic lung allograft dysfunction (CLAD). We hypothesize that donor-derived cell-free DNA (%ddcfDNA), at the time of RVI predicts CLAD progression. We followed 39 LTRs with RVI enrolled in the Genomic Research Alliance for Transplantation for 1 year. Plasma %ddcfDNA was measured by shotgun sequencing, with high %ddcfDNA as ≥1% within 7 days of RVI. We examined %ddcfDNA, spirometry, and a composite (progression/failure) of CLAD stage progression, re-transplant, and death from respiratory failure. Fifty-nine RVI episodes, 38 low and 21 high %ddcfDNA were analyzed. High %ddcfDNA subjects had a greater median %FEV
Identifiants
pubmed: 35729715
doi: 10.1111/ajt.17125
pii: S1600-6135(22)29972-9
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2560-2570Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201800082P
Pays : United States
Informations de copyright
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Gregson AL. Infectious triggers of chronic lung allograft dysfunction. Curr Infect Dis Rep. 2016;18(7):21. doi:10.1007/s11908-016-0529-6
Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant. 2009;28(9):888-893. doi:10.1016/j.healun.2009.04.022
Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175(5):507-513. doi:10.1164/rccm.200608-1079OC
Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170(2):181-187. doi:10.1164/rccm.200310-1359OC
Permpalung N, Sait AS, Bazemore K, Avery RK, Mathew J, Shah PD. Human metapneumovirus and parainfluenza virus infections in lung transplant recipients: the effects on lung allograft and clinical outcomes. Transplant. 2021;105:2625-2631. doi:10.1097/TP.0000000000003645
Permpalung N, Thaniyavarn T, Saullo JL, et al. Oral and inhaled ribavirin treatment for respiratory syncytial virus infection in lung transplant recipients. Transplant. 2020;104(6):1280-1286. doi:10.1097/TP.0000000000002985
de Zwart A, Riezebos-Brilman A, Lunter G, et al. Respiratory syncytial virus, human metapneumovirus, and parainfluenza virus infections in lung transplant recipients: a systematic review of outcomes and treatment strategies. Clin Infect Dis. 2022;74(12):2252-2260. doi:10.1093/cid/ciab969
Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019;69(7):1192-1197. doi:10.1093/cid/ciy1047
Sayah DM, Koff JL, Leard LE, Hays SR, Golden JA, Singer JP. Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection. Clin Transplant. 2013;27(1):E64-E71. doi:10.1111/ctr.12054
Ambrosioni J, Bridevaux P-O, Aubert J-D, Soccal P, Wagner G, Kaiser L. Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. J Clin Virol. 2015;64:1-5. doi:10.1016/j.jcv.2014.12.021
Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62(3):313-319. doi:10.1093/cid/civ871
Colombat M, Groussard O, Lautrette A, et al. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection. Clinicopathologic correlations during the first 6 months after lung transplantation. Hum Pathol. 2005;36(4):387-394. doi:10.1016/j.humpath.2005.01.022
Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant. 2008;27(10):1128-1134. doi:10.1016/j.healun.2008.06.014
Bhorade SM, Husain AN, Liao C, et al. Interobserver variability in grading transbronchial lung biopsy specimens after lung transplantation. Chest. 2013;143(6):1717-1724. doi:10.1378/chest.12-2107
Mahan LD, Points A, Mohanka MR, et al. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021;23(4):e13661. doi:10.1111/tid.13661
Testaert H, Bouet M, Valour F, et al. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study. Clin Microbiol Infect. 2021;27(6):897-903. doi:10.1016/j.cmi.2020.07.050
Heldman MR, Kates OS, Safa K, et al. COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study. Am J Transplant. 2021;21(8):2774-2784. doi:10.1111/ajt.16692
Royer P-J, Olivera-Botello G, Koutsokera A, et al. Chronic lung allograft dysfunction: a systematic review of mechanisms. Transplant. 2016;100(9):1803-1814. doi:10.1097/TP.0000000000001215
De Vlaminck I, Martin L, Kertesz M, et al. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015;112(43):13336-13341. doi:10.1073/pnas.1517494112
Agbor-Enoh S, Wang Y, Tunc I, et al. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine. 2019;40:541-553. doi:10.1016/j.ebiom.2018.12.029
Agbor-Enoh S, Jackson AM, Tunc I, et al. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis. J Heart Lung Transplant. 2018;37(7):925-932. doi:10.1016/j.healun.2018.01.1305
Keller M, Bush E, Diamond JM, et al. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). J Heart Lung Transplant. 2021;40(6):488-493. doi:10.1016/j.healun.2021.02.008
Khush KK, De Vlaminck I, Luikart H, Ross DJ, Nicolls MR. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res. 2021;7(1). doi:10.1183/23120541.00462-2020
Jang MK, Tunc I, Berry GJ, et al. Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. J Heart Lung Transplant. 2021;40(8):822-830. doi:10.1016/j.healun.2021.04.009
Bazemore K, Rohly M, Permpalung N, et al. Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury. J Heart Lung Transplant. 2021;40(11):1454-1462. doi:10.1016/j.healun.2021.05.012
Peghin M, Hirsch HH, Len Ó, et al. Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study. Am J Transplant. 2017;17(5):1304-1312. doi:10.1111/ajt.14042
Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010;31(2):243-254. doi:10.1055/s-0030-1249120
Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116(4):617-623. doi:10.1016/S0022-5223(98)70168-0
Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14(3):479-485.
Ammerman E, Sweet SC, Storch GA, et al. Epidemiology and persistence of rhinovirus in pediatric lung transplantation. Transpl Infect Dis. 2020;22:e13422. doi:10.1111/tid.13422
Manuel O, Estabrook M, American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13511. doi:10.1111/ctr.13511
Gunasekaran M, Bansal S, Ravichandran R, et al. Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection. J Heart Lung Transplant. 2020;39(4):379-388. doi:10.1016/j.healun.2019.12.009
Permpalung N, Bazemore K, Avery RK, Mathew J, Shah PD. Human metapneumovirus infections in lung transplant recipients: the effects on lung allograft and clinical outcomes. J Heart Lung Transplant. 2020;39(4):S203. doi:10.1016/j.healun.2020.01.814
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35(4):397-406. doi:10.1016/j.healun.2016.01.1223
Agbor-Enoh S, Tunc I, De Vlaminck I, et al. Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. J Heart Lung Transplant. 2017;36(9):1004-1012. doi:10.1016/j.healun.2017.05.026
Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi:10.1681/ASN.2016091034
Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493-503. doi:10.1016/j.healun.2019.03.009